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Abstract Matrix metalloproteinase-9 (MMP-9) is produced by
the inactive proform and activated by a proteolytic process.
However, it has not been reported to produce the active form
directly from cells, which has hindered the research to elicit the
physiological roles of this enzyme. In this study, we prepared
mutant MMP-9 containing the furin-recognizing sequence in the
prodomain and showed that the mutant MMP-9 was secreted as
the active form directly from CHO-K1 cells and primary
hepatocytes after the gene was transfected. The secreted
MMP-9 showed proteolytic activity without further activation
and degraded collagen IV in vitro. In addition, the transfection of
the gene into the liver resulted in the efficient expression of active
MMP-9 in the liver and the serum in vivo. ß 2001 Published by
Elsevier Science B.V. on behalf of the Federation of European
Biochemical Societies.
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1. Introduction
Matrix metalloproteinases (MMPs) are a large family of
zinc-requiring matrix degrading enzymes. They have been im-
plicated in various physiological aspects such as invasive cell
behavior, embryonic development and organ morphogenesis.
In these processes, the degradation of basement membrane is
the critical event. The basement membrane is essentially com-
posed of type IV collagen, the molecule that gelatinases, an
MMP subclass, preferentially degrade. Therefore, it is thought
that the roles of gelatinases are signi¢cant in the physiological
processes. The gelatinases, also called type IV collagenases as
a result of their activity, include MMP-2 (gelatinase A) and
MMP-9 (gelatinase B). These MMPs are thought to be acti-
vated by ‘cysteine switch’ model. In this model, coordination
of the zinc molecule in the active site of the catalytic domain
with a sulfhydryl-containing cysteine residue in the conserved
sequence [1] located at the C-terminus of the propeptide re-
gion is required for latency. Disruption of the zinc^sulfhydryl
ligation by sulfhydryl reagents or removal of the prodomain
by denaturants, oxidants, and proteases allows coordination
of the zinc with a water molecule, resulting in the formation
of an active enzyme. Compared to MMP-2, which is activated
by MT1-MMP, the physiological activation mechanism of
MMP-9 has not been clear. Since MMP-9 is produced as an
inactive proform and processed to an active form by cleaving
the prodomain, the physiological functions of active MMP-9
have not been clear yet. So far, the only way to examine the
functional mechanism of MMP-9 is employing MMP-9-de¢-
cient mice [2^4]. However, the distribution of these mice is
restricted, and without active MMP-9 production from cells
it is di⁄cult to perform in vitro cellular experiments. Accord-
ing to the protein structure and the activation mechanism of
MMP, some constitutive active mutant forms of MMPs were
prepared by modifying the cysteine-switch region [5]. How-
ever, modifying the improper amino acids in the region often
results in the impairment of normal protein folding, which
resulted in the failure of active enzyme production [6]. Thus,
the method can not be applicable to any MMP. In fact, prep-
aration by this method of active forms of only a few MMPs
such as MMP-3 and MMP-13 have been reported [5^8]. In
contrast, some MMPs such as stromelysin-3 (MMP-11) and
MT1-MMP (MMP-14) contain the furin-cleavage sequence in
the prodomain and are expressed from cells as processed,
active forms [9].
Furin, a proprotein-processing enzyme, is a member of the
yeast Kex2 family of endoproteases that contain a subtilisin-
like serine-protease domain as an active site [10]. Furin cleaves
the carboxy-terminus of the unique consensus sequence
[RX(K/R)R]. In this paper, we have tried another method
to produce active MMPs directly from cells by inserting fur-
in-recognition sequence in the prodomain. Accordingly, we
applied this activation mechanism to MMP-9 and demon-
strated that transfection of this mutant gene into cultured cells
resulted in the direct production of active MMP-9 in vitro and
in vivo. Since furin is distributed more or less in virtually all
tissues [11], the active MMP-9 can be produced from almost
all cells. This mutant form will be a useful tool to examine the
roles of MMP-9. In addition, this activation method can be
applicable to any MMP since this method modi¢es the only
prodomain after folding but not the critical region, the ‘cys-
teine switch’ domain.
2. Materials and methods
2.1. Reagents and cells
Plasmid DNA, pGEL2-SK containing mouse full length MMP-9
gene [12] was kindly provided by Dr. H. Tanaka (Shionogi and
Co., Ltd., Osaka, Japan), and mouse full length furin gene in pSVL
plasmid [10] and CHO-K1 cells were obtained from American Type
Culture Collection (ATCC) (MD, USA). A mammalian expression
vector, pTracer-CMV plasmid, was purchased from Invitrogen (San
Diego, CA, USA). Primary mouse hepatocytes were isolated from
adult ICR mice (8-weeks-old) by the modi¢ed methods as described
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[13]. Cells were transfected with the reagents, Lipofectamine (Gibco
BRL, Bethesda, MD, USA) for CHO-K1 and FuGene (Roche Di-
agonostics, Inc., Tokyo, Japan) for primary hepatocytes following the
manufacturer’s instruction. Other reagents were purchased from Sig-
ma Chemical Co. Ltd. (St. Louis, MO, USA) unless speci¢cally de-
scribed.
2.2. Preparation of mutant MMP-9 containing a furin-recognition
sequence in the prodomain (fuMMP-9) and other mutant genes
MMP-9-containing plasmid, pGEL2-SK, contains SmaI sites in the
prodomain (at 167) and hemopexin domain (at 1915). Therefore,
SmaI digestion generated plasmid lacking 167^1915 of MMP-9. The
product was puri¢ed and dephosphorylated (SmaI-pGEL2). At the
same time, using primers containing the RRKR sequence codon in
the sense (P1: 5P-GGAGGAAACGTGCCGCCCAGATGATG; P2:
5P-GGGACGACGCGGGAG), the fragment (167^1915) of MMP-9
containing the RRKR sequence in the prodomain was prepared by
PCR. The fragment was then ligated to the dephosphorylated SmaI-
pGEL2. The sequence of the mutant MMP-9 was con¢rmed by se-
quence analysis. The MMP-9 fragment was cut out by EcoRI-NotI
digestion and inserted into the expression vector, pTracer-CMV at the
multicloning site. The furin insert was also cut out from pSVL by
EcoRI digestion and inserted into pTracer-CMV. Other point-mu-
tated MMP-9 forms (CA-MMP-9; cysteine100 was changed to Arg,
LA-MMP-9; leucine50 to Arg, LC-MMP-9; both C100 and L50 to
Fig. 1. Design of various mouse mutant MMP-9. Structural image
of MMP-9 and the mutation sites are depicted. Five mutants were
designed (fuMMP-9, dMMP-9, CA-MMP-9, LA-MMP-9, CL-
MMP-9).
Fig. 2. Production of furin-dependent active MMP-9 with fuMMP-9 gene in di¡erent cell types. A: CHO-K1 cells were transfected with
wtMMP-9 or fuMMP-9 plasmids. 24 h after transfection, the supernatants were harvested and subjected to zymography. Lane 1: wtMMP-9,
lane 2: fuMMP-9. *Latent form, **active form, ***autocleaved fragment. B and C: Isolated hepatocytes were transfected with wtMMP-9,
fuMMP-9 alone or fuMMP-9 plus furin plasmids. 24 h after transfection, the supernatants were harvested and subjected to gelatin zymography
(B) or proteolytic assay against type IV collagen (C). B: Lane 1, control; lane 2, wtMMP-9; lane 3, fuMMP-9; lane 4, fuMMP-9 plus furin.
*Latent form, **active form. C: Lane 1, control; lane 2, gelatinase (100 Wg/ml); lane 3, APMA (1.5 mM); lane 4, wtMMP-9; lane 5, fuMMP-
9 alone; lane 6, fuMMP-9 plus furin; lane 7, APMA-treated wtMMP-9. The arrows are the major type IV collagen bands.
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Arg) (Fig. 1) which are supposedly active according to the modi¢ca-
tion results of MMP-3 [5] were prepared by QuickChange Site-Di-
rected Mutagenesis kit (Stratagene, La Jolla, CA, USA). The deleted
mutant of MMP-9 (dMMP-9) which has the same DNA sequence of
the cleaved, active MMP-9 without prodomain was also prepared by
PCR and inserted into pTracer-CMV.
2.3. Gelatin zymography
The supernatants from culture cells or lysates from tissues were
electrophoresed on 7.5% SDS^polyacrylamide gel containing 0.1%
gelatin. The gel was washed with 0.1% Triton X-100 solution for 30
min and then incubated at 37‡C overnight in the activation bu¡er (50
mM Tris^HCl, pH 7.4, 0.2 M NaCl, 5 mM CaCl2, and 0.02% NaN3).
After staining with CBB R-250, the gelatinolytic activities were de-
tected as clear bands against the blue background. In some cases,
MMPs in supernatants were concentrated by gelatin^Sepharose (Phar-
macia, Uppsala, Sweden). The contrast images of zymography were
inverted to facilitate the band detection.
2.4. Type IV collagen proteolytic activity
Active MMP-9 was con¢rmed by both the mobility shift of the
bands in zymography and proteolytic activity of collagen type IV.
The supernatants from cultured cells or lysates from tissues (1 Wl)
were incubated with 3 Wg collagen type IV (Sigma) (1 Wl) in the
activating bu¡er (8 Wl) at 37‡C overnight. These samples were then
subjected to SDS^PAGE on 7.5% gel (10 Wl/lane).
2.5. In vivo gene transfection
In vivo transfection into the liver was performed as described [14].
Brie£y, genes in the expression vector, pTracer (100 Wg/mouse) were
intravenously injected into mice with 6 ml Ringer solution, which
results in the speci¢c expression of transfected genes in hepatocytes
[14]. 9 h after the administration, the serum and liver tissue lysates
were subjected to zymography.
3. Results and discussion
3.1. Furin-dependent, direct production of active MMP-9 from
cultured cells
First, we transfected either wild type MMP-9 (wtMMP-9)
or fuMMP-9 into CHO-K1 cells and examined the gelatino-
lytic activities of the supernatants. As shown in Fig. 2A,
wtMMP-9 was secreted in the supernatant and appeared as
a single band which was corresponding to the latent form. In
contrast, fuMMP-9 was spontaneously processed when se-
creted from the transduced cells and approximately half of
the gelatinolytic activity was found in the position of active
MMP-9. Part of the active form was autodegraded and ap-
peared as a small fragment at the lower position.
Next, we con¢rmed furin dependency of fuMMP-9 employ-
ing primary mouse hepatocytes since, contrary to the in vivo
situation, these cells express little furin in vitro without any
stimulation [15]. Primary hepatocytes did not spontaneously
express any detectable amount of MMPs in the culture super-
natant and the transient transfection of wtMMP-9 gene re-
sulted in production of the intact, inactive form (Fig. 2B, lane
2). Hepatocytes transfected with fuMMP-9 only also pro-
duced the inactive form of MMP-9 (Fig. 2B, lane 3). In con-
trast, cotransfection of fuMMP-9 and furin genes into these
cells produced the active form of MMP-9 in the supernatants
(Fig. 2B, lane 4). These results demonstrate that the inactive
form produced from cells transfected with fuMMP-9 gene was
processed to the active form in a furin-dependent manner. The
reason why approximately only half of the amount protein
was processed to the active form is unclear at present. Ac-
cording to the putative mechanism wherein furin processes the
prodomain of the inactive form at the ¢rst step, and then the
processed protein autoactivates and become the active form at
the second step, the autoactivation at the second step may not
be su⁄cient. The details of the mechanism, however, remain
to be solved. The processed active form from fuMMP-9
showed strong proteolytic activity against type IV collagen
(Fig. 2C). The supernatant from fuMMP-9 and furin cotrans-
fected hepatocytes (lane 6) contained almost the same proteo-
lytic activity as commercial gelatinase (lane 2) or chemically
activated (APMA-treated) MMP-9 (lane 7). It is notable that
neither wtMMP-9 nor fuMMP-9 without furin cotransfection
did not show any proteolytic activity (lanes 4 and 5). These
results also demonstrate furin-dependent, direct production of
active MMP-9 from cells. Interestingly, despite the production
Fig. 3. Comparative production of active MMP-9 by fuMMP-9
gene to other mutants. Mutant MMP-9s were transfected into pri-
mary cultured hepatocytes and 24 h later, the supernatants were
harvested and subjected to zymography (A) or proteolytic activity
assay against type IV collagen (B and C). A: Lane 1, control;
lane 2, wtMMP-9; lane 3, fuMMP-9 alone; lane 4, fuMMP-9 plus
furin; lane 5, dMMP-9; lane 6, CA-MMP-9; lane 7, LA-MMP-9;
lane 8, CL-MMP-9. *Latent form, **active form. B: Lane 1, con-
trol ; lane 2, wtMMP-9; lane 3, fuMMP-9 alone; lane 4, fuMMP-9
plus furin; lane 5, dMMP-9; lane 6, CA-MMP-9; lane 7, LA-
MMP-9; lane 8, CL-MMP-9; lane 9, APMA-treated wtMMP-9.
C: Lane 1, control; lane 2, APMA-treated wtMMP-9; lane 3,
APMA-treated wtMMP-9 with EDTA (10 mM); lane 4, fuMMP-9
plus furin; lane 5, fuMMP-9 plus furin with EDTA.
FEBS 25075 23-7-01
Y. Watanabe et al./FEBS Letters 502 (2001) 63^67 65
of active MMP-9, the morphology of the producing cells did
not change when these cells were cultured on either collagen-
coated or gelatin-coated plates. This may be because these
cells produce a non-substrate extracellular matrix for MMP-
9, such as ¢bronectin or because MT-MMPs rather than se-
creted MMPs have a more profound e¡ect on cellular func-
tions in the microenvironments as described [16].
3.2. Comparison to other types of mutant MMP-9
Some active MMPs could be prepared by point mutations
in cysteine-switch domain or prodomain [5,6]. Therefore, we
compared the point-mutated forms of MMP-9 to fuMMP-9 in
the production and activation. We prepared three types of
point mutants according to the previous report describing
point-mutated active MMP-3 [5]. CA-MMP-9 has a mutation
in the cysteine of the ‘cysteine switch’. LA-MMP-9 has a point
mutation in the leucine of the prodomain. CL-MMP-9 has
both mutations in the same molecule. Besides, we prepared
deleted MMP-9 (dMMP-9) which has the same codon se-
quence of active MMP-9. When these mutants were trans-
fected into primary hepatocytes (these cells are proper to ex-
amine MMP production assay since, as described above,
primary hepatocytes do not produce any MMPs in the super-
natant), the secretion of CA-MMP-9, CL-MMP-9 or dMMP-
9 in small amounts was detected (Fig. 3A). The gelatinolytic
activity was detected in the supernatant of only LA-MMP-9-
transfected cells. However, the active form was detected in
small amounts (lane 6) compared to fuMMP-9 with furin
(lane 4). The proteolytic activities in the supernatants of these
mutants re£ected the production pattern. As shown in Fig.
3B, only fuMMP-9 with furin showed the su⁄cient proteolytic
activity against type IV collagen compared to other mutant
forms. These results suggest two important points, i.e. the
cysteine in the cysteine switch is important for the protein
secretion, probably because the cysteine function as a key
amino acid for the regulation of protein folding. The second
point is that the point mutation in the prodomain is insu⁄-
cient for the processing of inactive MMP-9 to active MMP-9,
di¡erent from the case of MMP-3.
The proteolytic activities of the supernatants were com-
pletely blocked by the addition of EDTA in the assay system,
which also demonstrated the active function of MMP-9
(Fig. 3C).
3.3. Expression of active MMP-9 by fuMMP-9 gene in vivo
We next tried to induce the expression of active MMP-9
using fuMMP-9 in vivo since in vivo expression is required for
the investigation of the physiological functions. Transduction
into the liver was performed by intravenous injection of plas-
mid DNA [14]. As shown in Fig. 4, transfection of MMP-9
genes in the liver resulted in high expression of the proteins in
both liver and serum. Mere injection of Ringer solution
slightly induced MMP-9 expression in both liver and serum.
This is probably because of the liver injury by the massive
volume of injection [14], for liver injury is thought to induce
MMP-9 expression in the liver [17]. Liver injury is also
thought to induce plasmin activation [18]. Interestingly, trans-
duced wtMMP-9 was activated in the liver but not in the
serum (Fig. 4A,B, lane 3). It is possible that the localized
activation of MMP-9 is due to the plasmin activation since
the plasmin system is involved in the processing of proMMP-9
to the active form [19]. In contrast, the activated form of
fuMMP-9 was detected in both the liver and serum of the
mice transfected with fuMMP-9 gene alone although the ac-
tive form was minor in the serum (lane 4). It is likely that the
endogenous furin activity in the liver is not su⁄cient to pro-
cess the large amount of transfected fuMMP-9. However, co-
transfection of fuMMP-9 plus furin genes resulted in strong
expression of active MMP-9 in both the liver and serum (lane
5). These results demonstrate that transduced fuMMP-9 was
processed by furin in vivo. To our knowledge, this is the ¢rst
successful report that active MMP-9 was systematically in-
duced in vivo. This fuMMP-9 can be a promising tool for
the physiological investigation of this molecule and therapeu-
tic purposes.
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